Lyra Therapeutics Terminates Material Agreement
Ticker: LYRA · Form: 8-K · Filed: Apr 17, 2026
Sentiment: neutral
Topics: agreement-termination, 8-k
TL;DR
Lyra Therapeutics terminated a big deal on 4/13/26. Details scarce.
AI Summary
Lyra Therapeutics, Inc. filed an 8-K on April 17, 2026, to report the termination of a material definitive agreement. The filing indicates that this termination occurred on April 13, 2026. No specific details about the agreement or the counterparty were provided in the filing.
Why It Matters
The termination of a material definitive agreement can significantly impact a company's operations, financial standing, and future strategic direction.
Risk Assessment
Risk Level: medium — Termination of a material definitive agreement can signal significant business or financial challenges.
Key Numbers
- 0001327273 — CIK Number (Identifier for Lyra Therapeutics, Inc.)
- 0001193125-26-160421 — SEC Accession Number (Unique identifier for this specific filing.)
Key Players & Entities
- Lyra Therapeutics, Inc. (company) — Filer
- 0001327273 (company) — CIK Number
- 2026-04-17 (date) — Filing Date
- 2026-04-13 (date) — Period of Report / Termination Date
- 480 ARSENAL WAY WATERTOWN MA 02472 (location) — Mailing and Business Address
FAQ
What was the material definitive agreement that was terminated?
The filing does not specify the details of the material definitive agreement that was terminated.
Who was the counterparty to the terminated agreement?
The filing does not disclose the name of the other party involved in the terminated agreement.
What are the reasons for the termination of the agreement?
The filing states the termination of a material definitive agreement but does not provide the reasons behind it.
What is the financial impact of this termination on Lyra Therapeutics?
The filing does not detail the financial implications of the agreement's termination.
When exactly did the termination of the agreement become effective?
The filing indicates the period of report is 2026-04-13, suggesting the termination was effective on or around this date.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 17, 2026 regarding Lyra Therapeutics, Inc. (LYRA).